← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Dupage Medical Technology, Inc.
Chicago, IL
$6,482,587
Total funding
5
Grants
Funding over time
peak $1.8M · FY2017–25$2M$1.5M$1M$500K$0
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$6,482,587 · 5
By mechanism
R44$3,992,547 · 2
N01$1,958,173 · 1
R43$531,867 · 2
Investigators at Dupage Medical Technology, Inc.
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Not enough data
Emerging Leaders
6–10 yrs in
All-Time
Most funded here, all years
Largest grants
Developing a new drug for treating myocardial ischemia/reperfusion injury$1,141,737
R44 · FY2022 · HL
Developing a new drug for treating myocardial ischemia/reperfusion injury$856,873
R44 · FY2021 · HL
DEVELOPING AN INHIBITOR OF INTEGRIN OUTSIDE-IN SIGNALING AS A NEW GENERATION OF ANTI-THROMBOTIC DRUG - VITA 2$825,010
N01 · FY2018 · HL
IGF::OT::IGF DEVELOPING AN INHIBITOR OF INTEGRIN OUTSIDE-IN SIGNALING AS A NEW GENERATION OF ANTI-THROMBOTIC DRUG$792,047
N01 · FY2017 · HL
Targeting integrin outside-in signaling for treating sepsis$776,915
R44 · FY2021 · HL
Targeting integrin outside-in signaling for treating sepsis$634,951
R44 · FY2022 · HL
Targeting integrin outside-in signaling for treating sepsis$582,071
R44 · FY2023 · HL
IGF::OT::IGF DEVELOPING AN INHIBITOR OF INTEGRIN OUTSIDE-IN SIGNALING AS A NEW GENERATION OF ANTI-THROMBOTIC DRUG$341,116
N01 · FY2019 · HL
A new drug to treat transplant-associated renal ischemia-reperfusion injury$306,867
R43 · FY2025 · DK
Targeting integrin outside-in signaling for treating sepsis$225,000
R43 · FY2018 · HL